Abstract
Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have